Skip to main content
Premium Trial:

Request an Annual Quote

Minerva Licenses Osmetech's SAM Tech to Study Functional Proteomics

NEW YORK (GenomeWeb News) — Minerva Biotechnologies has non-exclusively licensed Osmetech’s self-assembling monolayer technology for use with its proprietary nanoparticle technology, Osmetech said today.
Osmetech said Minerva will use the SAM technology to study signal enhancement, drug design, drug screening, and functional proteomics.
Osmetech exclusively licensed the technology from Harvard University a decade ago. The IP was invented in part by Minerva founder and CSO Cynthia Bamdad.
SAM technology is used in biosensing to minimize background signal, provide for uniform functionalized attachment of molecules to surfaces, and reduce nonspecific aggregation events. 
Osmetech uses the technology with nucleic acid analyte diagnostics. For instance, late last year the company licensed the technology to Ohmx, which planned to use it in non-nucleic acid analyte detection schemes.
Osmetech is “currently in dialog” with an undisclosed number of other companies that have expressed interest, Edward Kreusser, Osmetech’s vice president of intellectual property and legal affairs, said in a statement.  
Financial terms of the agreement were not released.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.